A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment



Status:Completed
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any
Updated:4/29/2017
Start Date:May 26, 2015
End Date:April 5, 2017

Use our guide to learn which trials are right for you!

A Multicenter, Non-Interventional Study Evaluating Bleeding Incidence, Health-Related Quality of Life, and Safety in Patients With Hemophilia A Under Standard-of-Care Treatment

This non-interventional study will prospectively collect detailed, high-quality
documentation of bleeds, HRQoL, and safety in patients with hemophilia A with or without
FVIII inhibitors treated according to local routine clinical practice (receiving FVIII
replacement or bypassing agents as either episodic or prophylactic treatment). Actual
patients will be enrolled from routine clinical practice in this observational study.


Inclusion Criteria:

- Cohort A: Patients greater than or equal to (>/=) 12 years of age at time of informed
consent

- Cohort A: Diagnosis of congenital hemophilia A of any severity and documented history
of high-titer inhibitor (that is, >/= 5 Bethesda units [BU])

- Cohort B: Pediatric patients less than (<) 12 years of age

- Cohort B: Diagnosis of congenital hemophilia A of any severity and documented history
of high-titer inhibitor (that is, >/=5 BU)

- Cohort C: Patients >/=12 years of age

- Cohort C: Diagnosis of congenital hemophilia A and FVIII activity <1 percent (%)

- Cohort C: No prior history of a positive inhibitor against FVIII

Exclusion Criteria:

- Prior RO5534262 (not applicable if patient agrees that prior RO5534262 will preclude
participation in a future investigational RO5534262 study)

- Bleeding disorder other than congenital hemophilia A

- Ongoing (or planned during the study) immune tolerance induction therapy with FVIII
or FVIII prophylaxis if currently/previously exposed to an inhibitor

- Previous or concomitant thromboembolic disease

- Known human immunodeficiency virus (HIV) infection with cluster of differentiation
(CD) 4 count <200 cells per microliter (cells/mcL)
We found this trial at
11
sites
3901 Beaubien Street
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
New Orleans, Louisiana 70112
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
520 East 70th Street
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
700 Southwest Campus Drive
Portland, Oregon 97201
?
mi
from
Portland, OR
Click here to add this to my saved trials
Santa Monica, California 90403
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3970 Reservoir Road Northwest
Washington, D.C., District of Columbia 20007
?
mi
from
Washington, D.C.,
Click here to add this to my saved trials